

DAFTAR PUSTAKA

- Alatab S, Sepanlou SG, Ikuta K, Vahedi H, Bisignano C, Safiri S, et al. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *The Lancet Gastroenterology & Hepatology*. 2020. 5:17–30. [https://doi.org/10.1016/S2468-1253\(19\)30333-4](https://doi.org/10.1016/S2468-1253(19)30333-4).
- Alatawi H, Mosli M, Saadah OI, Annese V, Al-Hindi R, Alatawy M, et al. Attributes of intestinal microbiota composition and their correlation with clinical primary non-response to anti-TNF- α agents in inflammatory bowel disease patients. *Bosn J Basic Med Sci*. 2022. 22:412–26. <https://doi.org/10.17305/bjbms.2021.6436>.
- Aminoff MJ, Daroff RB. *Encyclopedia of the Neurological Sciences*. ScienceDirect. 2014. <http://www.sciencedirect.com:5070/referencework/9780123851581/encyclopedia-of-the-neurological-sciences> (accessed March 30, 2023).
- Antoni L, Nuding S, Wehkamp J, Stange EF. Intestinal barrier in inflammatory bowel disease. *World J Gastroenterol*. 2014. 20:1165–79. <https://doi.org/10.3748/wjg.v20.i5.1165>.
- Antoniou E. The TNBS-induced colitis animal model: An overview. *Annals of Medicine and Surgery*. 2016.
- Arasu MV, Al-Dhabi NA, Ilavenil S, Choi KC, Srigopalram S. In vitro importance of probiotic *Lactobacillus plantarum* related to medical field. *Saudi J Biol Sci*. 2016. 23:S6–10. <https://doi.org/10.1016/j.sjbs.2015.09.022>.
- Bamola VD, Dubey D, Samanta P, Kedia S, Madempudi RS, Neelamraju J, et al. Effect of *Bacillus coagulans* Unique IS-2 in Inflammatory Bowel Disease (IBD): A Randomized Controlled Trial 2021:2021.07.18.21260556. <https://doi.org/10.1101/2021.07.18.21260556>.
- Ban Q-Y, Liu M, Ding N, Chen Y, Lin Q, Zha J-M, et al. Nutraceuticals for the Treatment of IBD: Current Progress and Future Directions. *Front Nutr*. 2022. 9:794169. <https://doi.org/10.3389/fnut.2022.794169>.
- Bevivino G, Monteleone G. Advances in understanding the role of cytokines in inflammatory bowel disease. *Expert Review of Gastroenterology & Hepatology*. 2018. 12:907–15. <https://doi.org/10.1080/17474124.2018.1503053>.
- Bilsborough J, Fiorino MF, Henkle BW. Select animal models of colitis and their value in predicting clinical efficacy of biological therapies in ulcerative colitis. *Expert Opinion on Drug Discovery*. 2021. 16:567–77. <https://doi.org/10.1080/17460441.2021.1851185>.

- Brenna Ø, Furnes MW, Drozdov I, Granlund A van B, Flatberg A, Sandvik AK, et al. Relevance of TNBS-Colitis in Rats: A Methodological Study with Endoscopic, Histologic and Transcriptomic Characterization and Correlation to IBD. *PLOS ONE*. 2013. 8:e54543. <https://doi.org/10.1371/journal.pone.0054543>.
- Bubnov RV, Babenko LP, Lazarenko LM, Mokrozub VV, Spivak MYa. Specific properties of probiotic strains: relevance and benefits for the host. *EPMA Journal*. 2018. 9:205–23. <https://doi.org/10.1007/s13167-018-0132-z>.
- Chen X, Zhao X, Wang H, Yang Z, Li J, Suo H. Prevent Effects of *Lactobacillus Fermentum* HY01 on Dextran Sulfate Sodium-Induced Colitis in Mice. *Nutrients*. 2017. 9:545. <https://doi.org/10.3390/nu9060545>.
- Chen Y, Zhang L, Hong G, Huang C, Qian W, Bai T, et al. Probiotic mixtures with aerobic constituent promoted the recovery of multi-barriers in DSS-induced chronic colitis. *Life Sciences*. 2020. 240:117089. <https://doi.org/10.1016/j.lfs.2019.117089>.
- Darmastuti A, Hasan PN, Wikandari R, Utami T, Rahayu ES, Suroto DA. Adhesion Properties of *Lactobacillus plantarum* Dad-13 and *Lactobacillus plantarum* Mut-7 on Sprague Dawley Rat Intestine. *Microorganisms*. 2021. 9:2336. <https://doi.org/10.3390/microorganisms9112336>.
- Donato-Capel L, Garcia-Rodenas CL, Pouteau E, Lehmann U, Srichuwong S, Erchner A, et al. Chapter 14 - Technological Means to Modulate Food Digestion and Physiological Response. In: Boland M, Golding M, Singh H, editors. *Food Structures, Digestion and Health*. San Diego: Academic Press. 2014. p. 389–422. <https://doi.org/10.1016/B978-0-12-404610-8.00014-1>.
- Ferrer-Picón E, Dotti I, Corraliza AM, Mayorgas A, Esteller M, Perales JC, et al. Intestinal Inflammation Modulates the Epithelial Response to Butyrate in Patients With Inflammatory Bowel Disease. *Inflammatory Bowel Diseases*. 2020. 26:43–55. <https://doi.org/10.1093/ibd/izz119>.
- Friedrich M, Pohin M, Powrie F. Cytokine Networks in the Pathophysiology of Inflammatory Bowel Disease. *Immunity*. 2019. 50:992–1006. <https://doi.org/10.1016/j.immuni.2019.03.017>.
- Gajendran M, Loganathan P, Jimenez G, Catinella AP, Ng N, Umapathy C, et al. A comprehensive review and update on ulcerative colitis. *Disease-a-Month*. 2019. 65:100851. <https://doi.org/10.1016/j.disamonth.2019.02.004>.
- Guan Q, Zhang J. Recent Advances: The Imbalance of Cytokines in the Pathogenesis of Inflammatory Bowel Disease. *Mediators of Inflammation*. 2017. 2017:e4810258. <https://doi.org/10.1155/2017/4810258>.
- Hemarajata P, Versalovic J. Effects of probiotics on gut microbiota: mechanisms of intestinal immunomodulation and neuromodulation. *Therap Adv Gastroenterol*. 2013. 6:39–51. <https://doi.org/10.1177/1756283X12459294>.

- Iyer SS, Cheng G. Role of Interleukin 10 Transcriptional Regulation in Inflammation and Autoimmune Disease. *Crit Rev Immunol*. 2012. 32:23–63.
- Ju T, Willing BP. Isolation of Commensal *Escherichia coli* Strains from Feces of Healthy Laboratory Mice or Rats. *Bio Protoc*. 2018. 8:e2780. <https://doi.org/10.21769/BioProtoc.2780>.
- Lavelle A, Sokol H. Gut microbiota-derived metabolites as key actors in inflammatory bowel disease. *Nat Rev Gastroenterol Hepatol*. 2020. 17:223–37. <https://doi.org/10.1038/s41575-019-0258-z>.
- Leccese G, Bibi A, Mazza S, Facciotti F, Caprioli F, Landini P, et al. Probiotic *Lactobacillus* and *Bifidobacterium* Strains Counteract Adherent-Invasive *Escherichia coli* (AIEC) Virulence and Hamper IL-23/Th17 Axis in Ulcerative Colitis, but Not in Crohn's Disease. *Cells*. 2020. 9:1824. <https://doi.org/10.3390/cells9081824>.
- Lee C, Kim BG, Kim JH, Chun J, Im JP, Kim JS. Sodium butyrate inhibits the NF-kappa B signaling pathway and histone deacetylation, and attenuates experimental colitis in an IL-10 independent manner. *International Immunopharmacology*. 2017. 51:47–56. <https://doi.org/10.1016/j.intimp.2017.07.023>.
- Liu Y, Fang H, Liu H, Cheng H, Pan L, Hu M, et al. Goji berry juice fermented by probiotics attenuates dextran sodium sulfate-induced ulcerative colitis in mice. *Journal of Functional Foods*. 2021. 83:104491. <https://doi.org/10.1016/j.jff.2021.104491>.
- Lorenzo JM, Munekata PE, Dominguez R, Pateiro M, Saraiva JA, Franco D. Chapter 3 - Main Groups of Microorganisms of Relevance for Food Safety and Stability: General Aspects and Overall Description. In: Barba FJ, Sant'Ana AS, Orlien V, Koubaa M, editors. *Innovative Technologies for Food Preservation*. Academic Press. 2018. p. 53–107. <https://doi.org/10.1016/B978-0-12-811031-7.00003-0>.
- Loubet Filho PS, Dias TO, Reis VH de OT, Moya AMTM, Santos EF dos, Cazarin CBB. Feed your gut: Functional food to improve the pathophysiology of inflammatory bowel disease. *Journal of Functional Foods*. 2022. 93:105073. <https://doi.org/10.1016/j.jff.2022.105073>.
- Martini E, Krug SM, Siegmund B, Neurath MF, Becker C. Mend Your Fences: The Epithelial Barrier and its Relationship With Mucosal Immunity in Inflammatory Bowel Disease. *Cellular and Molecular Gastroenterology and Hepatology*. 2017. 4:33–46. <https://doi.org/10.1016/j.jcmgh.2017.03.007>.
- Mayangsari Y, Suzuki T. Resveratrol Ameliorates Intestinal Barrier Defects and Inflammation in Colitic Mice and Intestinal Cells. *J Agric Food Chem*. 2018. 66:12666–74. <https://doi.org/10.1021/acs.jafc.8b04138>.

- Mustika S, Triana N. The Prevalence, Profile, and Risk Factor of Patient with Ulcerative Colitis at Dr. Saiful Anwar Malang General Hospital. *The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy*. 2016. 17:16–20.
- Naissinger da Silva M, Tagliapietra BL, Flores V do A, Pereira dos Santos Richards NS. *In vitro* test to evaluate survival in the gastrointestinal tract of commercial probiotics. *Current Research in Food Science*. 2021. 4:320–5. <https://doi.org/10.1016/j.crfs.2021.04.006>.
- Neurath MF. Cytokines in inflammatory bowel disease. *Nat Rev Immunol*. 2014. 14:329–42. <https://doi.org/10.1038/nri3661>.
- Nishida A, Inoue R, Inatomi O, Bamba S, Naito Y, Andoh A. Gut microbiota in the pathogenesis of inflammatory bowel disease. *Clin J Gastroenterol*. 2018. 11:1–10. <https://doi.org/10.1007/s12328-017-0813-5>.
- Oh SY, Cho K-A, Kang JL, Kim KH, Woo S-Y. Comparison of experimental mouse models of inflammatory bowel disease. *International Journal of Molecular Medicine*. 2014. 33:333–40. <https://doi.org/10.3892/ijmm.2013.1569>.
- Padoan A, Musso G, Contran N, Basso D. Inflammation, Autoinflammation and Autoimmunity in Inflammatory Bowel Diseases. *Current Issues in Molecular Biology*. 2023. 45:5534–57. <https://doi.org/10.3390/cimb45070350>.
- Parada Venegas D, De la Fuente MK, Landskron G, González MJ, Quera R, Dijkstra G, et al. Short Chain Fatty Acids (SCFAs)-Mediated Gut Epithelial and Immune Regulation and Its Relevance for Inflammatory Bowel Diseases. *Frontiers in Immunology*. 2019. 10.
- Pilarczyk Zurek M, Zwolinska Weislo M, Mach T, Okon K, Adamski P, Heczko PB, et al. Influence of *Lactobacillus* and *Bifidobacterium* Combination on the Gut Microbiota, Clinical Course, and Local Gut Inflammation in Patients with Ulcerative Colitis: A Preliminary, Single-center, Open-label Study. *J Prob Health*. 2017. 05. <https://doi.org/10.4172/2329-8901.1000163>.
- Plaza-Diaz J, Ruiz-Ojeda FJ, Gil-Campos M, Gil A. Mechanisms of Action of Probiotics. *Advances in Nutrition*. 2019. 10:S49–66. <https://doi.org/10.1093/advances/nmy063>.
- Poritz LS, Harris LR, Kelly AA, Koltun WA. Increase in the Tight Junction Protein Claudin-1 in Intestinal Inflammation. *Dig Dis Sci*. 2011. 56:2802–9. <https://doi.org/10.1007/s10620-011-1688-9>.
- Purnomo HD, Kusuma RA, Sianturi E, Haroen RF, Solichin MR, Nissa C, et al. The Effects of Hepatogomax Enteral Formula on Systemic Inflammation, Caecum Short-Chain Fatty Acid Levels, and Liver Histopathology in Thioacetamide-Induced Rats. *Journal of Nutrition and Metabolism*. 2023. 2023:e2313503. <https://doi.org/10.1155/2023/2313503>.

- Rahayu ES, Cahyanto MN, Sarwoko M-A, Haryono P, Windiarti L, Sutriyanto J, et al. EFFECTS OF CONSUMPTION OF FERMENTED MILK CONTAINING INDIGENOUS PROBIOTIC LACTOBACILLUS PLANTARUM DAD-13 ON THE FECAL MICROBIOTA OF HEALTHY INDONESIAN VOLUNTEERS. *International Journal of Probiotics and Prebiotics*. 2016. 11:91–8.
- Rahayu ES, Mariyatun M, Putri Manurung NE, Hasan PN, Therdtatha P, Mishima R, et al. Effect of probiotic *Lactobacillus plantarum* Dad-13 powder consumption on the gut microbiota and intestinal health of overweight adults. *WJG*. 2021. 27:107–28. <https://doi.org/10.3748/wjg.v27.i1.107>.
- Rahayu ES, Rusdan IH, Athennia A, Kamil RZ, Pramesi PC, Marsono Y, et al. Safety Assessment of Indigenous Probiotic Strain *Lactobacillus plantarum* Dad-13 Isolated from *Dadih* Using Sprague Dawley Rats as a Model. *American Journal of Pharmacology and Toxicology*. 2019. 14:38–47. <https://doi.org/10.3844/ajptsp.2019.38.47>.
- Reeves PG, Nielsen FH, Fahey GC. AIN-93 Purified Diets for Laboratory Rodents: Final Report of the American Institute of Nutrition Ad Hoc Writing Committee on the Reformulation of the AIN-76A Rodent Diet. *The Journal of Nutrition*. 1993. 123:1939–51. <https://doi.org/10.1093/jn/123.11.1939>.
- Santana PT, Rosas SLB, Ribeiro BE, Marinho Y, de Souza HSP. Dysbiosis in Inflammatory Bowel Disease: Pathogenic Role and Potential Therapeutic Targets. *International Journal of Molecular Sciences*. 2022. 23:3464. <https://doi.org/10.3390/ijms23073464>.
- Selvamani S, Mehta V, Ali El Enshasy H, Thevarajoo S, El Adawi H, Zeini I, et al. Efficacy of Probiotics-Based Interventions as Therapy for Inflammatory Bowel Disease: A Recent Update. *Saudi Journal of Biological Sciences*. 2022. 29:3546–67. <https://doi.org/10.1016/j.sjbs.2022.02.044>.
- Shen Z-H, Zhu C-X, Quan Y-S, Yang Z-Y, Wu S, Luo W-W, et al. Relationship between intestinal microbiota and ulcerative colitis: Mechanisms and clinical application of probiotics and fecal microbiota transplantation. *WJG*. 2018. 24:5–14. <https://doi.org/10.3748/wjg.v24.i1.5>.
- Shin Y, Han S, Kwon J, Ju S, Choi TG, Kang I, et al. Roles of Short-Chain Fatty Acids in Inflammatory Bowel Disease. *Nutrients*. 2023. 15:4466. <https://doi.org/10.3390/nu15204466>.
- Silva I, Solas J, Pinto R, Mateus V. Chronic Experimental Model of TNBS-Induced Colitis to Study Inflammatory Bowel Disease. *International Journal of Molecular Sciences*. 2022. 23:4739. <https://doi.org/10.3390/ijms23094739>.
- Spiller R, Major G. IBS and IBD — separate entities or on a spectrum? *Nat Rev Gastroenterol Hepatol*. 2016. 13:613–21. <https://doi.org/10.1038/nrgastro.2016.141>.

- Suroto DA, Hasan PN, Rahayu ES. Genomic insight of two indigenous probiotics *Lactobacillus plantarum* Dad-13 and *Lactobacillus plantarum* Mut-7 from different origins of Indonesian fermented foods. *Biodiversitas*. 2021. 22. <https://doi.org/10.13057/biodiv/d221233>.
- Tatiya-aphiradee N, Chatuphonprasert W, Jarukamjorn K. Immune response and inflammatory pathway of ulcerative colitis. *Journal of Basic and Clinical Physiology and Pharmacology*. 2019. 30:1–10. <https://doi.org/10.1515/jbcpp-2018-0036>.
- Taverniti V, Koirala R, Dalla Via A, Gargari G, Leonardis E, Arioli S, et al. Effect of Cell Concentration on the Persistence in the Human Intestine of Four Probiotic Strains Administered through a Multispecies Formulation. *Nutrients*. 2019. 11:285. <https://doi.org/10.3390/nu11020285>.
- Trejo-Vazquez F, Garza-Veloz I, Villela-Ramirez GA, Ortiz-Castro Y, Mauricio-Saucedo P, Cardenas-Vargas E, et al. Positive association between leptin serum levels and disease activity on endoscopy in inflammatory bowel disease: A case-control study. *Exp Ther Med*. 2018. 15:3336–44. <https://doi.org/10.3892/etm.2018.5835>.
- Wong W-Y, Chan BD, Leung T-W, Chen M, Tai WC-S. Beneficial and anti-inflammatory effects of formulated prebiotics, probiotics, and synbiotics in normal and acute colitis mice. *Journal of Functional Foods*. 2022. 88:104871. <https://doi.org/10.1016/j.jff.2021.104871>.
- Xia Y, Chen Y, Wang G, Yang Y, Song X, Xiong Z, et al. *Lactobacillus plantarum* AR113 alleviates DSS-induced colitis by regulating the TLR4/MyD88/NF- κ B pathway and gut microbiota composition. *Journal of Functional Foods*. 2020. 67:103854. <https://doi.org/10.1016/j.jff.2020.103854>.
- Yasueda A, Mizushima T, Nezu R, Sumi R, Tanaka M, Nishimura J, et al. The effect of *Clostridium butyricum* MIYAIRI on the prevention of pouchitis and alteration of the microbiota profile in patients with ulcerative colitis. *Surg Today*. 2016. 46:939–49. <https://doi.org/10.1007/s00595-015-1261-9>.
- Yu LC-H. Microbiota dysbiosis and barrier dysfunction in inflammatory bowel disease and colorectal cancers: exploring a common ground hypothesis. *J Biomed Sci*. 2018. 25:79. <https://doi.org/10.1186/s12929-018-0483-8>.
- Zhang Z, Zhang H, Chen T, Shi L, Wang D, Tang D. Regulatory role of short-chain fatty acids in inflammatory bowel disease. *Cell Communication and Signaling*. 2022. 20:64. <https://doi.org/10.1186/s12964-022-00869-5>.